Twist Bioscience (NASDAQ:TWST) shares are trading higher on Tuesday after the company announced the launch of two coronavirus antibody panels to expedite research for COVID-19.
Twist Bioscience is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology.
The company's DNA synthesis platform utilizes proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead.
Twist Bioscience shares were trading up 0.99% at $59.21 on Tuesday. The stock has a 52-week high of $60.96 and a 52-week low of $18.52.